Rituximab immunotherapy for non-Hodgkin's lymphoma

Cancer Biother Radiopharm. 1999 Aug;14(4):241-50. doi: 10.1089/cbr.1999.14.241.

Abstract

Rituximab, a chimeric monoclonal antibody targeting the CD20 antigen on B lymphocytes, is now the standard treatment for relapsed, low-grade or follicular non-Hodgkin's lymphoma.

Publication types

  • Review

MeSH terms

  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Murine-Derived
  • Antigens, CD / immunology
  • Antigens, CD20 / immunology
  • Antineoplastic Agents / therapeutic use*
  • B-Lymphocytes / immunology
  • Clinical Trials as Topic
  • Humans
  • Lymphoma, Non-Hodgkin / drug therapy*
  • Lymphoma, Non-Hodgkin / immunology
  • Rituximab

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Antigens, CD
  • Antigens, CD20
  • Antineoplastic Agents
  • Rituximab